Abstract
The Boston Carpal Tunnel Questionnaire (BCTQ) is a scale that has been developed specifically for carpal tunnel syndrome (CTS). It consists of the Functional Status Scale (FSS) and the Symptom Severity Scale (SSS). It is the most widely used patient reported outcome measure in CTS and has been validated in many languages. Although already widely used, psychometric properties of the Dutch version of the BCTQ are yet unknown. The aim of this study was to assess the validity, reliability, responsiveness, and acceptability of the Dutch version. Moreover, this paper focuses the longitudinal validity (the use after an intervention) of the BCTQ, which has not been investigated before. A total of 180 patients completed the BCTQ in addition to a six-point Likert scale for perceived improvement, before and about 6–8 months after carpal tunnel release (CTR). Principal factor analysis revealed that the FSS is unidimensional, consisting of a single latent factor (“functionality”) and has a high internal consistency (Cronbach's α = 0.825). However, the SSS has three dimensions, which are all highly internally consistent: “daytime symptoms” (Cronbach's α = 0.805), “nighttime symptoms” (Cronbach's α = 0.835), and “operational capacity” (Cronbach's α = 0.723). Post-treatment, the FSS still consisted of one factor, but the SSS changed in dimensionality, as it had only two factors left post-treatment. The ΔFSS and ΔSSS had good correlation with the six-point Likert scale for perceived improvement (r = 0.524; p < 0.01 and r = 0.574; p < 0.01, respectively), a moderate correlation between FSS and pinch grip (r = 0.259; p < 0.01) was found, and a weak correlation between SSS and pinch grip (r = 0.231; p < 0.01) was found. Standard Response Mean for FSS and SSS was 0.76 and 1.49, respectively. Effect size was 0.92 and 1.96, respectively, both indicating a good responsiveness. Response rate was high (82–84%). We concluded that the Dutch version of the BCTQ has a proper reliability, validity, responsiveness, and acceptability to assess the symptom severity and functional disabilities of CTS patients. Because of multidimensionality, we would recommend to create sum scores of the four different dimensions instead of two. Caution is required when interpreting the results postoperatively, due to the insufficient longitudinal validity of the SSS.
Highlights
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and can cause paresthesia, numbness, pain, and weakness in the territory innervated by the median nerve [1, 2]
Exclusion criteria were age under 18, a significant language barrier, a history or clinical signs of polyneuropathy or known hereditary neuropathy with liability to pressure palsies, previous trauma, or surgery to the wrist, a history of rheumatoid arthritis, diabetes mellitus, thyroid disease, alcoholism, arthrosis of the wrist, pregnancy, or severe atrophy of the abductor pollicis brevis muscle (APB). They all completed the Dutch version of the Boston Carpal Tunnel Questionnaire (BCTQ) at inclusion (T1) and about 6–8 months after Carpal tunnel release (CTR) (T2)
A total of 229 patients were included in our study and underwent CTR
Summary
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and can cause paresthesia, numbness, pain, and weakness in the territory innervated by the median nerve [1, 2]. Carpal tunnel release (CTR) is considered the most effective treatment, as a favorable outcome on short term as well as long term has been demonstrated [3,4,5]. The quality of the applied scale will have a profound effect on the acquired results. It is advantageous to recall what exactly scaling instruments aim to do. Scales serve to measure traits that are an inherently unobservable concept by [1] assuming that patients’ true scores on the latent concept can be quantified on a continuum, [2] presenting patients with a set of questions (items) that are positioned on that continuum, and [3] aiming to infer patients’ position on that latent continuum by quantifying their answers on the items
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
